King of Prussia, PA, United States of America

Alexis Pual Godillot

This inventor holds 1 USPTO granted patent. Top assignee: Glaxosmithkline LLC. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alexis Pual Godillot. Retrieved from https://idiyas.com/inventor/alexis-pual-godillot

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Alexis Pual Godillot

Introduction

Alexis Pual Godillot is an accomplished inventor based in King of Prussia, PA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies with multiple specificities. His work has the potential to impact various therapeutic applications.

Latest Patents

Alexis holds a patent for a novel antibody that binds to human IL-8, Gro-alpha, Gro-beta, Gro-gamma, and ENA-78. This invention is crucial for advancing our understanding of immune responses and developing targeted treatments.

Career Highlights

Alexis is currently employed at GlaxoSmithKline LLC, where he continues to innovate and contribute to the field of pharmaceuticals. His expertise in antibody development has positioned him as a valuable asset in his organization.

Collaborations

He has collaborated with notable colleagues, including Eric Dobrzynski and Stephanie Jane Clegg, to further enhance the research and development efforts at GlaxoSmithKline.

Conclusion

Alexis Pual Godillot's work exemplifies the spirit of innovation in biotechnology. His contributions to antibody research are paving the way for future advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…